New Data Confirms Adherence Is Key to Blood Pressure Control
"Drugs Don't Work in Patients Who Don't Take Them":
A new analysis presented at ESC Congress 2026 puts hard numbers behind something many GPs have long suspected: it isn't just which antihypertensive you prescribe that determines cardiovascular protection. It's whether the patient actually takes it.
The key takeaways
- A large trial-based analysis examined what happens to cardiovascular outcomes when patients don't take their blood pressure medication as prescribed.
- Patients who stuck closely to their treatment saw real reductions in cardiovascular events. Patients who regularly missed doses did not.
- The authors argue that adherence assessment and support deserve a far more central place in routine hypertension management.
Why this matters
Hypertension remains one of the biggest drivers of disease burden worldwide, affecting an estimated 1.4 billion adults aged 30–79. Blood pressure-lowering medication is one of the most effective tools we have for reducing cardiovascular risk — yet roughly half of patients don't take it as prescribed.
Until now, the evidence linking poor adherence to worse outcomes has come largely from observational studies, which are vulnerable to confounding. Presenter Miss Qianqian Yang (University of Oxford, UK) and colleagues set out to test the true causal impact of adherence using randomised trial data instead.
What they did
The team pooled patient-level data from 91,339 participants across nine randomised trials, each comparing an antihypertensive regimen against a comparator (placebo or a less intensive regimen). Patients who took at least 80% of their assigned treatment were classified as having higher adherence; those below that threshold were classified as lower adherence.
What they found
Even within the relatively controlled setting of clinical trials, adherence drifted downward over time — from 88% of patients classified as higher-adherence in year one to just 79% by year five.
The consequences were clear:
- Systolic BP reduction (intervention vs. comparator) Higher adherence 5.2 mmHg Lower adherence 3.0 mmHg
- Major CV disease* reduction (intervention vs. comparator) Higher adherence 11% (significant) Lower adherence No significant reduction
*Stroke, myocardial infarction, or heart failure/ischaemic heart disease causing death or hospitalisation.
In other words, the cardiovascular protection conferred by treatment intensification was essentially concentrated among patients who actually took their medication as prescribed.
As Miss Yang put it, the results reinforce a familiar clinical adage: "drugs don't work in patients who don't take them."
The practical implication for hypertension care
The authors suggest adherence assessment and patient education should move from an afterthought to a routine part of hypertension management, alongside practical strategies to support it:
- Simplifying regimens wherever possible
- Using single-pill combinations to reduce daily medication burden
- Favouring longer-acting agents, where an occasional missed dose has less impact on control
Professor Felix Mahfoud, Chair of the ESC Communication Committee, echoed this call for a change in everyday practice, noting that non-adherence has for too long been overlooked as a cause of uncontrolled hypertension, and encouraging clinicians to have open, non-judgemental conversations with patients about the barriers they face in taking their medication.
Bottom line for GPs
Uncontrolled blood pressure despite an "adequate" regimen shouldn't automatically prompt escalation to a new or additional drug. Before intensifying treatment, it's worth asking a simple, non-judgemental question about how consistently the current regimen is actually being taken — and considering whether simplification, combination pills, or longer-acting agents might close the gap more effectively than adding another prescription.
